EHA2023 Hybrid Congress

The IELSG37 study provides robust evidence that radiotherapy can be omitted in patients with primary mediastinal B cell lymphoma who have achieved a complete metabolic response with dose-intensive immunochemotherapy.

Dutch population-based research provides insight into the most commonly used treatment strategies for people with relapsed and refractory peripheral T-cell lymphoma.

Hemochromatosis C282Y homozygotes have an increased risk of diabetes even if they have normal levels of iron, transferrin saturation or ferritin. Current treatment, which focuses on lowering ferritin, may not adequately reduce the risk of diabetes.

The outcomes and safety of axicabtagene ciloleucel in patients with relapsing or refractory follicular lymphoma appear to be consistent with the outcomes and safety observed in the ZUMA-5 study in daily practice.

Ruxolitinib improves spleen volume and total symptom score in patients with myelofibrosis regardless of anemia and transfusion status at baseline. This is evident from a post hoc analysis of the two COMFORT studies.

Romiplostim combined with ciclosporin A could serve as a new first-line treatment for patients with aplastic anemia. This is the conclusion of Japanese researchers based on phase II/III results.

A Dutch population study shows that survival of patients with early relapsing/refractory diffuse large cell B cell lymphoma treated with second-line intensive therapy with or without autologous stem cell transplantation is downright poor.

Interim results of the CLIMB THAL-111 study show that exagamglogene autotemcel has the potential to cure patients with transfusion-dependent β-thalassemia with a single treatment.

The HOVON 141/VISION study shows that protein profiles at baseline in patients with chronic lymphocytic leukemia are predictive of MRD status after 15 months of treatment with venetoclax plus ibrutinib.

Treatment with pacritinib is a safe and effective pretransplantation strategy for patients with myelofibrosis. This emerges from the final analysis of the phase II HOVON134 trial.

Ziftomenib has demonstrated encouraging clinical activity and manageable safety in people with relapsed or refractory acute myeloid leukemia carrying NPM1 mutations in the early-phase KOMET-001 trial.

The 6-year results from the CLL14 study confirm the long-term benefits of a 1-year regimen of venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia and co-existing conditions.

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and painful …

Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial …

Few studies have compared the relative effectiveness of different iron compounds on iron status in school-age children with iron deficiency anemia. The objective of this study was to compare the effect of iron amino acid chelated (AACI) …

Janus kinase 2 (JAK2) V617F mutation is present in most patients with polycythemia vera (PV). One persistently puzzling aspect unresolved is the association between JAK2V617F allele burden (also known as variant allele frequency) and the relevant …